Century Therapeutics, Inc. (IPSC)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Century Therapeutics, Inc. (IPSC)

Company Performance

Current Price

as of Oct 16, 2024

$1.57

P/E Ratio

N/A

Market Cap

$133M

Description

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Metrics

Overview

HQPhiladelphia, PA
SectorHealth Technology
IndustryBiotechnology
TickerIPSC
Price$1.57+4.67%

Trading Information

Market Cap$133.00M
Float38.15%
Average Daily Volume (1m)350,255
Average Daily Volume (3m)324,250
EPS-$2.04

Company

Revenue$2.04M
Rev Growth (1yr)678.79%
Net Income-$31.21M
Gross Margin-349.03%
EBITDA Margin-4,160.18%
EBITDA-$32.07M

EV$69.31M
EV/Revenue33.94
P/EN/A
P/S63.12
P/B0.60

Documents

Factset Street Account

Century Therapeutics to present initial data from ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in R/R CD19 positive B-cell lymphomas at ASH ($1.49, 0.00) (2023-11-02T13:03:40Z)

Century Therapeutics reports Q3 EPS ($0.55) vs FactSet ($0.51) [8 est, ($0.58)-(0.45)]; new CEO and new license agreement with FUJI Cellular Dynamics ($1.60, 0.00) (2023-11-09T12:23:18Z)